Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Samantha Hocking

A/Prof Samantha Hocking

Tirzepatide Compared to Semaglutide for Treatment of Obesity – Latest Evidence

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Genitourinary Syndrome of Menopause – Mythbusting for GPs

Prof Sonia Grover

Prof Sonia Grover

Dysmenorrhoea in Teens

Prof Paul Griffin

Prof Paul Griffin

Winter Virus Preparations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Martin MacDonald

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023